Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Budoprutug (TNT119) in Subjects With Primary Membranous Nephropathy (PMN)

NCT07096843 is registered in ClinicalTrials.gov with Climb Bio, Inc. as lead sponsor.

NCT NCT07096843
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07096843 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of Budoprutug (TNT119) in Subjects With Primary Membranous Nephropathy (PMN)
Lead sponsor
Climb Bio, Inc.
Phase
Phase 2
Overall status
Recruiting
Start date
August 25, 2025
Completion date
October 31, 2027
Enrollment
45 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

primary membranous nephropathy